Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid Structure

15 Dec 2022

Abstract excerpt

Lipid nanoparticles (LNPs) have delivered therapeutic RNA to hepatocytes in humans. Adsorption of apolipoprotein E (ApoE) onto these clinical LNP-mRNA drugs has been shown to facilitate hepatocyte entry via the low-density lipoprotein receptor (LDLR). Since ApoE-LDLR trafficking is conserved in mice, non-human primates, and humans, characterizing this mechanism eased clinical transition. Recently, LNPs have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to RNA Interference and Gene Delivery
Share to Systemic Lupus Erythematosus Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36521071
DOI: 10.1021/acs.nanolett.2c03741

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid StructurePMID 36521071Read ↗

Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle DeliverySemantic proximity Read ↗

Lipid Nanoparticles for In Vivo Lung Delivery of CRISPR-Cas9 Ribonucleoproteins Allow Gene Editing of Clinical TargetsSemantic proximity Read ↗

Extrahepatic, cell-specific delivery of LNPs through competitive inhibition of ApoE-mediated uptakeSemantic proximity Read ↗

A TLS11a-decorated ionizable lipid nanoparticle platform and a multilevel-validated CRISPR LDLR-knockout HepG2 model for hepatocyte-preferential mRNA deliverySemantic proximity Read ↗

2-arm-PEG-oligocations transiently shield the liver sinusoids to mitigate off-target hepatic expression of mRNA lipid nanoparticlesSemantic proximity Read ↗

Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic DiseasesSemantic proximity Read ↗

Lipid nanoparticles incorporating a GalNAc ligand enable in vivo liver <i>ANGPTL3</i> editing in wild-type and somatic <i>LDLR</i> knockout non-human primatesSemantic proximity Read ↗

Lipid nanoparticle technology for therapeutic gene regulation in the liverSemantic proximity Read ↗

Diverse lipid conjugates for functional extra-hepatic siRNA delivery <i>in vivo</i>Semantic proximity Read ↗

Lipid nanoparticle delivery of TALEN mRNA targeting LPA causes gene disruption and plasma lipoprotein(a) reduction in transgenic miceSemantic proximity Read ↗

Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imagingSemantic proximity Read ↗

Targeted delivery of RNA-based therapeutics enables functional analysis of macrophage subpopulationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.